ARCE Therapeutics, a Taiwan based biotech company, specializes in developing proprietary gene-modified cellular immunotherapies. ARCE’s CAR-T/NK cell therapy products are developed via three technologies, DashCAR®, MaxCAR®, and OneCAR®, for CAR immune cell therapy with high efficacy, safety, and durability, and thus to achieve a sustained improved response capable of conquering human diseases.
Company Details
- Employees
- 8
- Founded
- -
- Address
- 2f., No. 502, Ruiguang Road, Neihu District,taipei City 114,taiwan, Province Of China
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.arcetherapeutics.com/
- Keywords
- Cell Therapy, Biotech, CAR-T, CAR-NK.
- HQ
- Neihu District, Taipei City
Arce Therapeutics Questions
Arce Therapeutics's website is http://www.arcetherapeutics.com/
Arce Therapeutics's LinkedIn profile is https://tw.linkedin.com/company/arce-therapeutics-inc
Arce Therapeutics has
8 employees.
View email and phone details for 8
employees at Arce Therapeutics.
Arce Therapeutics's industry is
Biotechnology Research
Arce Therapeutics's top competitors are
森品統計品質工程顧問有限公司,
Oriongo,
Obi Pharma,
Compal,
Mycenax Biotech Inc.,
Elixiron Immunotherapeutics,
Global Bio & Investment Monthly,
Topaz Clinical Research,
Miltenyi Biotec,
Gssi Emprise Pvt Ltd.
Arce Therapeutics's categories are Biotechnology Research
Arce Therapeutics's founding year is 2020
